IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
← Ticker index
SRPT
Ticker

SRPT

Congressional Trades
2
by 1 members
Ticker disclosure brief

Congressional disclosure records for SRPT

A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.

Latest receipt
Gilbert Cisneros
SELL · 2025-04-14
Largest range
$1K – $15K
Gilbert Cisneros
Longest observed gap
22d
Gilbert Cisneros
Highest 30d vs SPY
-94.2%
Gilbert Cisneros
Purchase rows
0
0%
Sale rows
2
100%
Disclosed midpoint
$16K
range estimate
Unique Traders
1
members
Disclosure timing method

Observed filing gaps are not notice-date findings

The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.

Party Breakdown

Democrats2 · 100%
Republicans0 · 0%

Lobbying filings

all →
  • 2026-04-20$270K
    SAREPTA THERAPEUTICS INC.
    Duchenne Muscular Dystrophy and Rare Disease Patient Access to Treatments Newborn Screening for Rare Diseases Scientific Innovation in Healthcare Gene Therapies Artificial Intelligence and Data Governance
  • 2026-04-20$110K
    SAREPTA THERAPEUTICS
    Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
  • 2026-04-20$90K
    SAREPTA THERAPEUTICS
    federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting
  • 2026-01-20$230K
    SAREPTA THERAPEUTICS INC.
    Patient Access to Treatments Newborn Screening for Rare Diseases Scientific Innovation in Healthcare Gene Therapies Rare Diseases Artificial Intelligence and Data Governance
  • 2026-01-20$110K
    SAREPTA THERAPEUTICS
    Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
  • 2026-01-20$90K
    SAREPTA THERAPEUTICS
    federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting
  • 2025-10-20$110K
    SAREPTA THERAPEUTICS
    Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
  • 2025-10-20$80K
    SAREPTA THERAPEUTICS
    federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule
  • 2025-10-15$430K
    SAREPTA THERAPEUTICS INC.
    Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to the Inflation Reduction Act's prescription drug provisions Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance Tax issues related to research and development
  • 2025-07-21$80K
    SAREPTA THERAPEUTICS
    federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule
Loading trade analytics…

All Disclosed Trades

Page 1 · 2 of 2 shown
DateMemberActionAmountObserved GapReceipt
2025-04-14DGilbert CisnerosSELL$1K – $15K22dreceipt →
2025-04-14DGilbert CisnerosSELL$1K – $15K22dreceipt →

“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.